Stephen Q Wong
Overview
Explore the profile of Stephen Q Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1841
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roth S, Wilson K, Ramsay R, Mitchell C, Sampurno S, Pham T, et al.
Heliyon
. 2025 Jan;
11(1):e41364.
PMID: 39811281
Background: TG02 is a peptide-based cancer vaccine eliciting immune responses to oncogenic codon 12/13 mutations. This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted...
2.
Hollizeck S, Wang N, Wong S, Litchfield C, Guinto J, Ftouni S, et al.
Nat Commun
. 2024 Nov;
15(1):9876.
PMID: 39543119
The use of circulating tumour DNA (ctDNA) to profile mutational signatures represents a non-invasive opportunity for understanding cancer mutational processes. Here we present MisMatchFinder, a liquid biopsy approach for mutational...
3.
Fagery M, Khorshidi H, Wong S, Karanfil O, Emery J, IJzerman M
Pharmacoecon Open
. 2024 Oct;
9(1):147-160.
PMID: 39424759
Background: Cancer screening plays a critical role in early disease detection and improving outcomes. In Australia, established screening protocols for colorectal, breast and cervical cancer have significantly contributed to timely...
4.
Jones J, Jones K, Wong S, Whittle J, Goode D, Nguyen H, et al.
Neurooncol Adv
. 2024 Apr;
6(1):vdae041.
PMID: 38596716
Background: Liquid biopsy based on circulating tumor DNA (ctDNA) is a novel tool in clinical oncology, however, its use has been limited in glioma to date, due to low levels...
5.
Jones J, Nguyen H, Wong S, Whittle J, Iaria J, Stylli S, et al.
Neurooncol Adv
. 2024 Apr;
6(1):vdae027.
PMID: 38572065
Background: Circulating tumor DNA has emerging clinical applications in several cancers; however, previous studies have shown low sensitivity in glioma. We investigated if 3 key glioma gene mutations , ,...
6.
Tan L, Brown C, Mersiades A, Lee C, John T, Kao S, et al.
Nat Commun
. 2024 Feb;
15(1):1823.
PMID: 38418463
In this phase II, single arm trial (ACTRN12617000720314), we investigate if alternating osimertinib and gefitinib would delay the development of resistance to osimertinib in advanced, non-small cell lung cancer (NSCLC)...
7.
van der Pol Y, Moldovan N, Ramaker J, Bootsma S, Lenos K, Vermeulen L, et al.
Genome Biol
. 2023 Oct;
24(1):229.
PMID: 37828498
Background: Existing methods to detect tumor signal in liquid biopsy have focused on the analysis of nuclear cell-free DNA (cfDNA). However, non-nuclear cfDNA and in particular mitochondrial DNA (mtDNA) has...
8.
MacManus M, Kirby L, Blyth B, Banks O, Martin O, Yeung M, et al.
Clin Transl Radiat Oncol
. 2023 Oct;
43:100682.
PMID: 37808452
Background: The kinetics of circulating tumor DNA (ctDNA) release following commencement of radiotherapy or chemoradiotherapy may reflect early tumour cell killing. We hypothesised that an increase in ctDNA may be...
9.
Hasan A, Cremaschi P, Wetterskog D, Jayaram A, Wong S, Williams S, et al.
Nat Commun
. 2023 Aug;
14(1):4823.
PMID: 37563129
Despite initial responses to hormone treatment, metastatic prostate cancer invariably evolves to a lethal state. To characterize the intra-patient evolutionary relationships of metastases that evade treatment, we perform genome-wide copy...
10.
Fagery M, Khorshidi H, Wong S, Vu M, IJzerman M
Pharmacoeconomics
. 2023 Jun;
41(10):1229-1248.
PMID: 37351802
Background: Cancer-derived material circulating in the bloodstream and other bodily fluids, referred to as liquid biopsies (LBs), has become an appealing adjunct or alternative to tissue biopsies, showing vital promise...